Mounjaro & Snoring: Does GLP-1 Weight Loss Help Sleep Apnea? | Ueno Snoring Clinic

Mounjaro, a GIP/GLP-1 receptor agonist, has become fairly well known — and it’s not just highly effective for weight loss, but can also help with snoring treatment.

In this article, we take a detailed look at Mounjaro.

Ueno Snoring Clinic offers insurance-covered sleep testing and CPAP management, as well as self-pay laser treatment for snoring and medically supervised weight loss, tailored to your specific condition. If you’d like to find out which treatment fits you, please start with an initial consultation.
Details of the tests and treatments offered at Ueno Snoring Clinic can be found here

A Complete Comparison of CPAP Masks

We tried on and reviewed five different types of CPAP masks. 90% of CPAP comfort comes down to the mask.

Watch the video

Do you have to use CPAP forever? A specialist explains how to use CPAP

A detailed explanation of how to use CPAP, with a real demonstration of what it feels like to wear the device.

Watch the video

Ueno Snoring Clinic was featured on Fuji TV’s “Live News It!” and on FNN Prime Online

Watch our clinic’s examination and explanation of sleep disorders, snoring, and sleep apnea.

Watch the video

Ueno Snoring Clinic Director Sugaya featured on news every.

Ueno Snoring Clinic was featured in an article on Nippon TV’s “news every.”

Please take a look as a starting point for thinking about getting evaluated for snoring, sleep apnea, or other sleep disorders.

Read the article

Reviewed by Our Director

Kazuyuki Sugaya

Director, Ueno Snoring Clinic / Anesthesiologist

Our director, with over 20,000 general anesthesia cases, focuses primarily on the diagnosis and treatment of snoring and sleep apnea, offering care tailored to each patient. [Insurance-Covered] Ueno Snoring Clinic

This article was reviewed by our Director, Kazuyuki Sugaya, and explains accurate medical information about Mounjaro (tirzepatide) and its relationship to obesity-related snoring and sleep apnea syndrome in clear, accessible terms.

🩺Comprehensive Snoring Treatment at Ueno Snoring Clinic

The causes of snoring range from the structure of the throat to body weight. Ueno Snoring Clinic doesn’t rely on a single treatment approach — we’re set up to recommend the best plan for each patient from a broad, evidence-based range of options.

Insurance-Covered: Thorough Testing and Ongoing Treatment

Simplified and PSG testing: A precise analysis of your sleep condition
CPAP treatment: The standard treatment for moderate-to-severe apnea

Self-Pay: Address the Root Cause, Short-Term Focus

Snoring laser treatment: A non-surgical approach to the underlying cause
Medically supervised weight loss: Improving airway space through weight reduction

*As a clinic specializing in snoring treatment, we work to resolve “snoring that won’t stop” through both insurance-covered and self-pay options.

Our director’s book, “Curing Snoring with the Latest Treatments” (No.1 Amazon Bestseller in General Medicine, No.1 in Clinical Internal Medicine, No.2 in Home Medicine & Health) covers this topic in detail as well

New Book by Our Director

“Curing Snoring with the Latest Treatments”

A guide to the latest snoring treatments, written by an anesthesiologist who has overseen the sleep of more than 10,000 patients.

View on Amazon

Quick Answer

Mounjaro (tirzepatide) is a GIP/GLP-1 receptor agonist originally approved for type 2 diabetes, and its strong appetite-suppressing effect can produce weight loss of over 10–20%. In the 2024 SURMOUNT-OSA trial, it produced a significant improvement in AHI (apnea-hypopnea index) among patients with moderate-to-severe obstructive sleep apnea (OSA) who also had obesity, and the same compound became the first drug approved in the U.S. specifically for OSA treatment. In short, Mounjaro is effective for snoring caused by “obesity plus OSA” — it is not a medication for simple snoring driven by a slim build or the shape of the upper airway. In Japan, it is covered by insurance only as a diabetes medication; use for weight loss or snoring is self-pay, off-label treatment.

📋 What This Article Covers

What Mounjaro is, and how it works
The link between obesity, snoring, and sleep apnea
The clinical evidence for Mounjaro’s effect on sleep apnea syndrome
Whether Mounjaro helps with snoring alone (without obesity)
Side effects, risks, and how it’s used
Common questions, answered

Obesity is one of the causes of snoring, and lately weight-loss approaches using the long-acting GIP/GLP-1 receptor agonist “Mounjaro” have been getting attention. Around this trend, Japan’s Nikkei newspaper ran a report worth noting.

“Dieting With Diabetes Drug ‘Mounjaro’ — Experts Warn of Possible Side Effects”

A growing number of people are using a drug approved to treat diabetes for weight-loss purposes instead. While self-pay prescriptions outside insurance coverage aren’t illegal, rising demand raises the risk that patients who genuinely need the drug — such as those with diabetes — may struggle to obtain it. Given the risk of side effects, experts including the Japan Medical Association are cautioning against casual use.

— The Nikkei

With that context in mind, this article looks in detail at the safety and effectiveness of Mounjaro treatment for obesity.

What Is Mounjaro?

Mounjaro is tirzepatide, a GIP/GLP-1 receptor agonist, and in Japan it is approved mainly as a “type 2 diabetes treatment” (as of 2025). Use for obesity alone, or for “cosmetic dieting” purposes, is not covered by insurance in Japan and is, in principle, treated as off-label, self-pay use.

Its main effects:

Appetite suppression (a central nervous system effect)
Delayed gastric emptying
Increased insulin secretion and improved blood sugar control
As a result, significant weight loss (a reduction of over 10–20% is not uncommon)

It’s this powerful weight-loss effect that connects Mounjaro to snoring and sleep apnea.

Ueno Snoring Clinic offers insurance-covered sleep testing and CPAP management, as well as self-pay laser treatment for snoring, tailored to your specific condition. If you’d like to find out which treatment fits you, please start with an initial consultation.
Details of the tests and treatments offered at Ueno Snoring Clinic can be found here

The Link Between Snoring, Obesity, and Sleep Apnea

Much of what makes snoring a real concern comes down to obstructive sleep apnea (OSA).

Obesity increases fat around the pharynx
The base of the tongue collapses, narrowing the upper airway
Lying on your back and muscle relaxation narrow the airway further, leading to snoring and apnea

Epidemiological data also shows:

A 10% weight gain is associated with roughly a 30%+ worsening of AHI (apnea-hypopnea index)
Conversely, a 10% weight loss is associated with roughly a 25% improvement in AHI — indicating a strong correlation between body weight and OSA severity

So for someone with “obesity plus snoring (plus possibly daytime sleepiness),” weight loss is central to treatment — and this is where Mounjaro is often effective.

Mounjaro’s Effectiveness for Sleep Apnea Syndrome

(1) Evidence as a Weight-Loss Medication

In trials such as SURMOUNT, Mounjaro (tirzepatide) has:

Achieved weight loss of roughly 15–20%
Maintained that weight loss with continued use

A weight change of this scale is exactly the kind of impact one would expect to meaningfully affect snoring and sleep apnea syndrome.

(2) Direct Evidence for Sleep Apnea Syndrome

This is the important part.

In the 2024 SURMOUNT-OSA trial (tirzepatide vs. placebo), patients with obesity and moderate-to-severe sleep apnea syndrome showed:

A significant reduction in AHI (apnea-hypopnea index)
Weight loss, reduced hypoxic burden, and improvements in blood pressure and inflammatory markers
Improved sleep-related quality of life

Based on this, the U.S. FDA approved Zepbound (the same compound, tirzepatide) in December 2024 as the world’s first drug specifically approved “for moderate-to-severe sleep apnea syndrome with obesity.”

In other words, this can be interpreted as:

“It has been officially recognized, at the drug-approval level, that tirzepatide can improve obesity-driven sleep apnea and its related symptoms — including snoring — through weight loss.”

More broadly, GLP-1 and GIP/GLP-1 medications as a class have reported AHI-improving effects, and are increasingly seen as a new pharmacological option for obesity-related sleep apnea syndrome.

For Patients Finding CPAP Follow-Up Visits Difficult

Ueno Snoring Clinic has started offering online consultations for patients on CPAP treatment. If monthly or every-other-month in-person visits are difficult for you, please ask us whether you qualify for this option.

Is Mounjaro Effective for Snoring Alone?

Here we look at whether Mounjaro is effective for snoring that occurs without sleep apnea syndrome.

Cases Where It Can Be Expected to Help

Assuming:

Obesity (particularly a BMI around 30 or higher, with visceral fat)
Clear or strongly suspected OSA (moderate or higher): loud snoring, observed breathing pauses, daytime sleepiness, high blood pressure, and similar signs

In such patients:

Mounjaro/tirzepatide produces substantial weight loss
Fat around the pharynx and tongue base decreases, improving upper airway compliance
AHI drops → apnea decreases → snoring volume decreases and improves

This reasonable mechanism is already backed by clinical trial data.

So it can be said that:

For people with “obesity plus suspected OSA,” using tirzepatide appropriately can contribute to improving snoring as well
This is especially worth considering as a “treatment through weight loss” for obese OSA cases where CPAP simply isn’t sustainable

This much is supported by the evidence.

Cases Where It’s Unlikely to Help, or Isn’t Recommended

Conversely, in the following cases, there’s little justification for using Mounjaro specifically “for snoring”:

Non-obese to mildly obese individuals with simple snoring only — If the main cause is upper-airway anatomy (a small jaw, nasal congestion, sinusitis, an enlarged uvula or tonsils, etc.), the effect of a weight-loss drug is limited.
Off-label misuse in Japan — Prescribing it solely because “I want to fix my snoring” or “I want to lose weight,” without proper diagnosis and management, raises medical-ethics and legal concerns.
Using it “just briefly” to lose weight before an event — Weight, and snoring, tend to return after stopping, since there’s no plan for maintaining the results.

In conclusion:

Mounjaro can be a viable option for some patients with “obesity plus OSA-type snoring,” but it is not a medication for someone who is slim but has loud snoring.

Comparison: When Mounjaro Is Likely — and Unlikely — to Help With Snoring

Type	Main Conditions	Mounjaro’s Effect
Obesity + OSA type	BMI around 30+, with loud snoring, observed breathing pauses, daytime sleepiness, high blood pressure, and other signs strongly suggesting OSA	Clinical trials show AHI reduction and improved snoring through weight loss. Can be a viable option.
Non-obese to mildly obese, simple snoring	No obesity, or only mild; anatomical factors (small jaw, congestion, enlarged tonsils) are the main cause	The drug’s weight-loss effect is limited here; little basis for use targeting snoring
Short-term, event-driven dieting	No plan to continue; used briefly and then stopped	Weight and snoring tend to return after stopping; not recommended

Mounjaro’s Side Effects and Risks

Common side effects include:

Gastrointestinal symptoms: Nausea, vomiting, diarrhea, constipation, abdominal pain (relatively common)
Low blood sugar: Particularly when combined with sulfonylureas or insulin
Acute pancreatitis, gallstones, or cholecystitis: Abdominal pain warrants further evaluation
Dehydration and electrolyte imbalance
Muscle loss (sarcopenia) or nutritional deficiency from rapid weight loss
Restrictions on use during pregnancy or breastfeeding
Anaphylactic shock

Aside from acute pancreatitis, these are side effects that can occur with many medications in general, and none stand out as especially severe. Acute pancreatitis is thought to be a side effect somewhat specific to insulin-related regulation, but it doesn’t appear to occur very frequently.

In clinical practice, the most common side effects by far are constipation and nausea (an upset stomach). These are related to how the drug works: Mounjaro slows down digestion, which in turn slows bowel movement (contributing to constipation) and lengthens how long food stays in the stomach. That said, this same effect is also part of what helps suppress appetite.

How Mounjaro Is Used

Treatment usually starts with the 2.5mg formulation, which is used for about a week. Once stable, the dose is increased to 5.0mg, also used for about a week.

For weight-loss purposes, results vary, but using the 2.5mg formulation for about a month can lead to roughly 5kg of weight loss.

That said, individual results vary considerably, so please treat this only as a general guide.

Summary

In short: Mounjaro is a self-pay treatment option with clinical trial support for “moderate-to-severe sleep apnea syndrome with obesity,” but it isn’t suited to simple snoring driven by a slim build or anatomical factors. It should always be used under a doctor’s supervision, alongside diet and exercise.

Having used it myself and prescribed it to patients at our clinic, I’ve clearly noticed that this medication has a different level of effectiveness compared to earlier oral medications. When I ask fellow clinicians, most say the same thing — that Mounjaro “really works.” I’m personally cautious about its use for excessive dieting purposes, but for patients who have obesity-related symptoms such as snoring, sleep apnea, or high blood pressure — not just diabetes — I believe that using it at a low dose is often worth it, weighing the benefits against the side effects.

In Japan, it’s true that insurance coverage is limited to diabetes treatment. Even so, I don’t think it’s wrong to use Mounjaro, on a self-pay basis, to address obesity — a major risk factor for sleep apnea syndrome — and I believe it holds real value from a preventive-medicine standpoint, in helping prevent future obesity-related conditions.

That said, trying to lose weight with Mounjaro alone is risky. Combining it with diet and exercise remains, without question, the most effective and safest way to use it. If you’re struggling with obesity-related snoring, we’d encourage you to visit a medical institution.

Frequently Asked Questions

Q. Is Mounjaro covered by insurance?

A. In Japan, Mounjaro (tirzepatide) is covered by insurance only as a treatment for type 2 diabetes. Use for improving snoring or for weight loss is self-pay, off-label treatment.

Q. Can I get Mounjaro prescribed if I only want to treat my snoring?

A. There’s little basis for using Mounjaro for simple snoring without obesity. Its effectiveness has been shown specifically for “moderate-to-severe sleep apnea syndrome with obesity,” so we’d first confirm whether obesity and OSA are present through testing before deciding whether it’s appropriate.

Q. How long does it take to see results?

A. Treatment typically starts with the 2.5mg formulation, with the dose evaluated and adjusted weekly. Results vary, but some patients see around 5kg of weight loss after about a month on the 2.5mg dose. Improvement in snoring tends to appear gradually as weight decreases.

Q. Should I be worried about side effects?

A. The most common issues in clinical practice are digestive symptoms like constipation and nausea. There are reports of more serious side effects such as acute pancreatitis, though they don’t appear to be common. Risk varies depending on your medical history and other medications, so it should always be used under a doctor’s supervision.

Q. Can Mounjaro and CPAP be used together?

A. Yes, they can be combined. CPAP treats the apnea directly, while Mounjaro addresses the underlying issue through weight loss — so for obese OSA patients who struggle to stick with CPAP, combining or transitioning between the two is worth considering.

Q. Is Mounjaro treatment at Ueno Snoring Clinic covered by insurance or self-pay?

A. We offer it as self-pay treatment (medically supervised weight loss). We first confirm the relationship between obesity and sleep apnea through a consultation and testing, then recommend the best approach alongside other treatments such as CPAP or laser treatment for snoring.